Results 151 to 160 of about 176,127,593 (290)

An act concerning improvement of cardiac care

open access: yes, 2007
Title from cover.; "Public Act 05-167, An Act Concerning the Improvement of Cardiac Care ..."--p.
Connecticut. Cardiac Care Data Committee.
core  

Quality of Care and Quality of Life: Convergence or Divergence?

open access: yesHealth Services Insights, 2014
Wadi B. Alonazi, Shane A. Thomas
doaj  

Process-related determinants of quality of care for individuals with sickle cell disease in a tertiary facility in Ghana. [PDF]

open access: yesBMJ Open
Amoako KO   +7 more
europepmc   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

From tokenism to youth leadership in child and adolescent mental health research

open access: yesPublic Health Reviews
Sophie Mae Harrington   +7 more
doaj   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy